Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 13/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254023 | 1.00 | MMP2 (0.55) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2246516 | 1.00 | MMP2 (0.55) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2247125 | 0.88 | MMP8 (0.47) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2246745 | 0.87 | MMP2 (0.43) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2254027 | 0.85 | MMP2 (0.47) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2246519 | 0.85 | MMP2 (0.47) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL8222718 | 0.78 | MMP2 (0.59) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL2247506 | 0.77 | FOLH1 (0.52) | MMP2MMP8MMP12ADAMTS5FOLH1 | |
| SCHEMBL7317663 | 0.76 | MAPK1 (0.44) | MMP2MMP8MMP12ADAMTS5HTT | |
| SCHEMBL2248684 | 0.75 | FOLH1 (0.47) | MMP2MMP8MMP12FOLH1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | MMP2 49/4885MMP8 70/4885MMP12 54/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | MMP2 49/4885MMP8 70/4885MMP12 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.